Compounded Semaglutide vs Ozempic
Same Active Ingredient — Different Manufacturer, Cost, and Regulatory Status
Compounded semaglutide and Ozempic (brand semaglutide by Novo Nordisk) share the same active molecule. Compounded versions emerged during the FDA shortage period and can cost 60–90% less than brand Ozempic. However, the FDA declared the semaglutide shortage resolved in early 2025, restricting large-scale compounding. Quality, purity, and legality differ significantly. Track either in Shotlee to monitor your dose and response.
Key Differences
- →Same semaglutide molecule; produced by compounding pharmacies
- →Not FDA-approved — not individually reviewed for safety or potency
- →Typically supplied as multi-dose vial requiring insulin syringe
- →Cost: ~$100–400/month from legitimate pharmacies
- →Quality varies: 503B outsourcing facilities have stricter standards than 503A
- →Salt form may differ (sodium or acetate vs brand free base)
- →Legal access restricted after FDA removed shortage designation (2025)
- →FDA-approved (2017) for type 2 diabetes
- →Manufactured by Novo Nordisk under GMP standards
- →Supplied as pre-filled FlexTouch autoinjector pen
- →Cost: ~$900–1,100/month without insurance
- →Full batch testing, QC documentation, and standardised formulation
- →Proven absorption and clinical trial data (SUSTAIN programme)
- →Insurance coverage generally available for T2D indication
Head-to-Head Comparison
| Factor | Compounded Semaglutide | Ozempic |
|---|---|---|
| Active molecule | Semaglutide (same) | Semaglutide (Novo Nordisk)Best |
| FDA approval | Not FDA-approved | FDA-approved 2017 (T2D) |
| Manufacturing standard | 503A or 503B pharmacy (variable) | GMP-compliant Novo Nordisk facility |
| Monthly cost (US) | ~$100–400 | ~$900–1,100 |
| Insurance coverage | Not covered | Covered for T2D |
| Device format | Multi-dose vial + syringe | Pre-filled FlexTouch pen |
| Purity/potency testing | Varies; no mandatory batch testing | Full QC and batch documentation |
| Legal status (2025–26) | Restricted after shortage resolved | Fully legal and available |
| Efficacy data | Assumed equivalent if dosed correctly | SUSTAIN programme (established) |
| Salt form | May differ (sodium, acetate) | Standardised formulation |
Cost vs Brand
Choose Based on Your Goal
Safety and standardisation
Ozempic wins here. Brand semaglutide is GMP-manufactured, batch-tested, and has a well-documented clinical profile from SUSTAIN trials.
Cost access without insurance
Compounded semaglutide from a verified 503B pharmacy can be 60–90% cheaper. For uninsured patients who cannot access brand, it may be practical.
Injection device preference
Ozempic's FlexTouch pen is simpler to use and less prone to dosing errors. Compounded vials require accurate syringe drawing.
Verify FDA shortage status first
Check the current FDA shortage list before ordering compounded semaglutide. Legal access depends on whether shortage designation is active.
Insurance coverage for T2D
If you have type 2 diabetes, Ozempic insurance coverage makes it accessible. Compounded versions are almost never covered by insurance.
Dose accuracy matters
Compounded products have shown potency variation in third-party testing. Use a verified 503B pharmacy with published Certificate of Analysis.
The 2025 Regulatory Shift
Compounding of semaglutide was legally permitted during the FDA shortage period (2022–early 2025) under provisions in the Food, Drug, and Cosmetic Act that allow compounding of drugs on the shortage list. In early 2025, the FDA declared the semaglutide shortage resolved, restricting large-scale 503B compounding. Some 503A pharmacies may still compound for individual patients with documented needs.
Always verify your pharmacy's current registration status (503A or 503B), require a valid prescription, and ask for a Certificate of Analysis showing potency and sterility testing. Avoid any source that does not require a prescription — this is both illegal and unsafe.
For patients who cannot afford Ozempic, Novo Nordisk offers a patient assistance programme (NovoCare) and savings cards that can significantly reduce out-of-pocket costs for eligible commercially insured patients.
Compounded Semaglutide vs Ozempic: Frequently Asked Questions
They share the same active molecule but are not the same product. Ozempic is FDA-approved, manufactured under validated GMP processes by Novo Nordisk, and carries full clinical data. Compounded semaglutide is produced by compounding pharmacies without FDA approval and variable quality controls.
Large-scale compounding is restricted after FDA declared the semaglutide shortage resolved in early 2025. Some 503A pharmacies can still compound for individual patients with specific needs. Verify your pharmacy's current registration and consult your prescriber.
Ozempic lists at $900–1,100/month without insurance. Compounded semaglutide from legitimate pharmacies typically costs $100–400/month — a saving of 60–90%.
Third-party testing has found potency variation in some compounded products. Different salt forms (sodium or acetate vs brand) may affect bioavailability. Sterility concerns are managed by 503B facilities but less strictly controlled at 503A pharmacies.
Yes. Shotlee supports custom dose logging for compounded semaglutide from vials — you can enter any dose in mg, track your vial supply, and set weekly reminders.
Track Compounded or Brand Semaglutide in Shotlee
Custom vial dosing or standard pen steps — Shotlee handles both. Free.